Aclidinium Bromide
Phase 3Small molecule
AstraZenecaAclidinium Bromide is a small molecule that works as a Muscarinic Acetylcholine Receptor M3 Antagonist.[2] It is being investigated across 7 indications, with its most advanced program in Phase 3.[1]
Aclidinium Bromide is one of 176 small molecule programs targeting Emphysema. It is currently in Phase 3.
7
Indications
34
Total Trials
0
Active Trials
175
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1050 competitors in Asthma
#DrugCompanyPhaseTrials
1Aclidinium Bromide
AstraZenecaPhase 3
Veramyst
GSKPreclinical
Xolair
RochePreclinical
Singulair
AstraZenecaPreclinical
Nucala
GGlaxo Dba Glaxosmithkline
Preclinical
Celexa
AbbViePreclinical
Formoterol Fumarate
AstraZenecaPreclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Blood Withdrawn
Emergent BioSolutionsPreclinical
DUPIXENT
RegeneronPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease21 trials
Show 18 more trials
Efficacy and Safety4 trials
Cardiovascular2 trials
5 more indications
Monotherapy1 trial
Tics1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Aclidinium Bromide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Muscarinic Acetylcholine Receptor M3 Antagonist[2]
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company